// App-Quantinova.ai

2192 : Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose

Researchers

Presenter

  • Andrew H. Wei

Principal Investigators

  • Kimmo Porkka

  • Steve Knapper

  • Norbert Vey

  • Sebastian Scholl

  • Guillermo Garcia-Manero

  • Martin Wermke

  • Jeroen Janssen

  • Elie Traer

  • Sun Loo

  • Rupa Narayan

  • Natalia Tovar

  • Mika Kontro

  • Oliver Ottmann

  • Siyan Xu

  • Serena Liao

  • Andrew Stein

  • Fariba Khanshan

  • Purushotham Naidu

  • Na Zhang

  • Anisa Mohammed

  • Mikael L. Rinne

  • Haiying Sun

  • Andrew M. Brunner

  • Uma Borate

Medical Centers

  • The Alfred Hospital and Monash University, Melbourne, Australia

  • Dermatology Department, Hospital Clinic of Barcelona, Barcelona, Spain

  • Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology, Helsinki, Finland

  • Cardiff University, Cardiff, United Kingdom

  • Institut Paoli-Calmettes, Marseille, France

  • Essen University Hospital, Essen, Germany

  • 1.MD Anderson Cancer Center, Houston, TX

  • University Hospital Dresden, Dresden, Germany

  • Amsterdam University Medical Center, Location VU University Medical Center, Amsterdam, Netherlands

  • Oregon Health and Science University, Portland, OR

  • The Alfred Hospital, Melbourne, Australia

  • Massachusetts General Hospital, Boston, MA

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Novartis Institutes for BioMedical Research, Inc, Cambridge, MA

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

Locations

  • Australia

  • Spain

  • Finland

  • United Kingdom

  • France

  • Germany

  • United States

  • Netherlands

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Alpha-thalassemia myelodysplasia syndrome

  • Acute myelocytic leukemia

  • Solid malignancies

Biomarkers

  • Programmed cell death protein 1

  • Hormone receptor

Drug/Treatment

  • PDR001

  • Vidaza

  • Decitabine

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • NA

Study Id's

  • NCT02608268

  • NCT03066648

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved